Abstract
Sir, In a recent QJM paper, investigators at the Shaare Zedek Medical Center, Jerusalem studying the prospective utility of cefepime, piperacillin-tazobactam and meropenem recommended formal infectious disease consultation for their appropriate usage.1 Ideally, empirical treatment regimens with broad-spectrum and/or costly antimicrobials would be based on unit-specific data. Nevertheless, any retrospective data on the in-vitro susceptibility profile of bacteria encountered in local intensive care could help guide selection of an appropriate approach. Therapeutic intervention is immediate and cannot be linked with the in-vitro susceptibility profile of the isolates. Background information …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
